Landos Biopharma

Landos Biopharma is a clinical-stage biotechnology company focused on developing novel, first-in-class oral therapeutics for autoimmune diseases. The company operates in the biopharmaceutical market, targeting conditions such as ulcerative colitis and Crohn's disease. Landos Biopharma's lead asset, BT-11, is a small molecule currently in Phase 2 trials for ulcerative colitis, with plans for additional trials in Crohn's disease. Another promising candidate, NX-13, is in Phase 1 studies for inflammatory bowel disease. The company aims to transform the standard of care by identifying novel pathways at the interface of immunity and metabolism, providing safer and more effective treatment options for patients. Landos Biopharma generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. The company's diverse team fosters an environment of innovation, driving forward its mission to improve patient outcomes.

Keywords: autoimmune diseases, oral therapeutics, clinical-stage, biotechnology, ulcerative colitis, Crohn's disease, BT-11, NX-13, novel pathways, biopharmaceutical.